Hypertrophic Cardiomyopathy 2020

James Kogut, Eric D. Popjes

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

Purpose of Review: To briefly review the pathophysiology and natural history of hypertrophic cardiomyopathy (HCM) and to describe the diagnosis, assessment, and contemporary management strategies. Recent Findings: HCM-related mortality remains low; however, symptoms due in large part to LVOT obstruction remain a clinical dilemma. Several medical therapies have been shown to reduce symptoms and improve functional capacity, including several recent phase 2 clinical trials involving the novel myosin modulator mavacamten. In patients with refractory symptoms, septal reduction therapy or advanced therapies remain viable options in many cases. Summary: HCM is a complex and heterogeneous disease with diverse presentations and variable anatomy and clinical outcomes. The majority of patients will remain asymptomatic or with minimal symptoms and long-term survival remains high. For symptomatic patients, a variety of medical therapies, along with septal reduction therapies, have been shown to reduce symptoms and improve functional capacity.

Original languageEnglish (US)
Article number154
JournalCurrent Cardiology Reports
Volume22
Issue number11
DOIs
StatePublished - Nov 1 2020

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Hypertrophic Cardiomyopathy 2020'. Together they form a unique fingerprint.

Cite this